Blues News

“We will create chances”: Blues boss Karanka insists that poor goal return won’t last forever

Image for “We will create chances”: Blues boss Karanka insists that poor goal return won’t last forever

Looks like we’re all in this together.

All for one, and one for all, and whatever cliché phrases you wish to insert into the mix to talk about our lack of goals so far this season. That was the message that Aitor Karanka seemed to be giving out when he was discussing our lack of productivity up top.

Speaking after the game against Rotherham United at the weekend, the Blues boss said that it is going to take a team effort to get things up to a level where we don’t necessarily have to rely on the defence (who have made a marked improvement on last year’s numbers so far) to have to hold opponents at bay every single time:

“Work harder, work more on the training ground, to get Jon Toral fitter, to get Scotty Hogan fitter, to have Ivan Sanchez fitter, to have Jonathan Leko fitter, to have Dan Crowley. It has been a shame for him [Crowley] because I was going to put him on the pitch then with the penalty I had to change my mind.

With those players and with that quality we will create chances, we will score goals, the main thing is to show we are a consistent team.”

Will we score more goals than we did last season?





Which I think is an important message to strike if we want to improve on where we were last season. In 2019/20 we had Lukas Jutkiewicz and Scott Hogan way out in front in terms of goal scorers, with a defender in Kristian Pedersen coming in joint-third with four goals.

Now a defender scoring four a season isn’t so bad, but he shouldn’t be anywhere near the top of the scoring charts, and hopefully this season if we are to take a step forward then we’ll be getting more production from those midfield players chipping in when they are fit and ready to go.

What about you? Do you think that these players need to contribute more when it comes to scoring goals?

Share this article

1 comment

  • Brian Taylor says:

    Short answer is “No”. Looks like we will have few chances and will need clinical conversion and we don’t have that!

Leave a comment

Your email address will not be published.